# RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

> **NCT06468267** · PHASE2 · RECRUITING · sponsor: **Xianmin Song, MD** · enrollment: 50 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Thiotepa

## Key facts

- **NCT ID:** NCT06468267
- **Lead sponsor:** Xianmin Song, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2026-07-15
- **Final completion:** 2026-07-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06468267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06468267, "RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06468267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*